Century Therapeutics, Inc. (IPSC) Tops Q1 EPS by 96c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts IPSC Hot Sheet
Join SI Premium – FREE
Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q1 EPS of $0.89, $0.96 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $109.16 million versus the consensus estimate of $19.94 million.
For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- Lincoln Educational Services (LINC) 2300 contracts of March 25 calls trade
- STAAR Surgical (STAA) 2K contracts of November 30 calls trade, share price up 3.6%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
